Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents
ID: 359202Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359202
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents," aimed at soliciting research applications that tackle the methodological issues associated with clinical trials involving psychotomimetic agents (PMAs). The focus of this initiative is to enhance the understanding of the therapeutic effects of PMAs, such as psilocybin and MDMA, which have shown potential benefits for mental health disorders like depression and anxiety, thereby increasing confidence in clinical trial outcomes. The estimated total program funding is $5 million, with approximately five awards anticipated, and interested applicants are encouraged to engage with the FDA prior to submission to ensure compliance with regulatory requirements. For further inquiries, potential applicants can contact Jonathan Sabbagh, Ph.D., at jonathan.sabbagh@nih.gov or by phone at 301-793-3534. The synopsis is expected to be posted on September 3, 2025, with applications closing on November 3, 2025, and awards anticipated by July 1, 2026.

    Point(s) of Contact
    Jonathan Sabbagh, Ph.D. National Institute of Mental Health, NIMH
    (301) 793-3534
    jonathan.sabbagh@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.
    Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the funding opportunity titled "Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes" (PAR-25-206). This initiative aims to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions, focusing on aspects such as feasibility, tolerability, acceptability, safety, and potential effectiveness. The program is crucial for advancing mental health treatment and understanding, particularly for underserved populations, by gathering data that will inform larger-scale effectiveness trials. Interested applicants can apply for grants of up to $750,000 over a three-year period, with the submission window opening on January 5, 2025, and closing on January 7, 2028. For more information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-206.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Assessing the Feasibility of Incorporating Mechanisms in Multisite Clinical Trials of Mind and Body Interventions on Whole Person Health Restoration (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) aimed at supporting multi-site feasibility studies of mind and body interventions, such as meditation and yoga, to enhance whole person health restoration. The objective of this funding opportunity is to establish foundational work that will inform future large-scale clinical trials, focusing on the effectiveness of these interventions and their impact on emotional well-being. This initiative is particularly significant as it seeks to enhance the generalizability and reproducibility of findings through studies conducted across multiple geographically distinct sites. Interested applicants, particularly multidisciplinary teams with expertise in complementary health and clinical trial design, should prepare for the anticipated NOFO, which will utilize the R01 Clinical Trial Required activity code. For further inquiries, potential applicants can contact Dr. Jennifer N. Baumgartner at jennifer.baumgartner@nih.gov or by phone at 301-402-4084. The estimated synopsis post date is December 5, 2025, with a closing date expected on February 5, 2026, and project start date anticipated for July 1, 2026.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms." This initiative aims to fund research that investigates how various mind and body interventions, such as mindfulness meditation, yoga, and acupuncture, can enhance whole person health through mechanisms of emotional well-being. The program emphasizes the importance of understanding the biological mechanisms behind these interventions and their potential to improve health outcomes, addressing significant gaps in current research. The estimated total funding for this program is $2 million, with three awards expected to be granted. Interested applicants, particularly small businesses, can reach out to Erin Burke Quinlan, Ph.D., at erin.quinlan@nih.gov or by phone at 301-480-9483 for further information. The application process is set to open on October 14, 2025, with a closing date of December 15, 2025, and anticipated award announcements by July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Molecular and Neural Mechanisms of Non-Invasive Brain Stimulation to Treat Substance Use Disorders
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Molecular and Neural Mechanisms of Non-Invasive Brain Stimulation to Treat Substance Use Disorders," aimed at encouraging basic research on Non-Invasive Brain Stimulation (NIBS) techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). The objective is to elucidate the molecular, cellular, and circuit-level changes induced by NIBS protocols and to identify the mechanisms by which these techniques produce therapeutic effects in treating substance use disorders. This research is crucial as it seeks to optimize treatment parameters for addiction therapies, with an estimated total program funding of $3 million and an expected four awards to be made. Interested applicants, particularly small businesses with expertise in neuromodulation and addiction, should prepare for the application process, with the estimated synopsis post date set for March 5, 2026, and the estimated award date on April 1, 2027. For further inquiries, contact Subramaniam Ananthan, Ph.D., at sam.ananthan@nih.gov or call 301-435-2199.